Toggle light / dark theme

Autonomous microfactory turns digital files into DNA for power-free preservation

According to projections, the volume of digital data created, captured, copied and consumed worldwide will reach 175 zettabytes (ZB) in 2026. This is equivalent to the storage capacity of billions of hard drives, such as those found in our laptops. With the rise of artificial intelligence, this global ‘datasphere’ continues to expand at an exponential rate.

Thanks to its remarkable storage capacity and longevity, synthetic DNA is emerging as a potentially revolutionary medium for storing information.

“In theory, one gram of DNA could store the equivalent of the digital collections of the world’s largest libraries for tens of thousands of years,” explains Pierre-Yves Burgi, deputy director of the Division of Information and Communication Systems and Technologies (DISTIC) at UNIGE.

Stronger cholesterol treatment shrinks more plaque in heart arteries, new clinical trial finds

Atherosclerosis is a condition in which cholesterol and fat gradually accumulate inside the walls of medium and large arteries, forming a sticky deposit called plaque. As these deposits grow, they narrow the arteries, restricting the flow of oxygen-rich blood to vital tissues and organs. Over time, this buildup can lead to ischemic heart disease (IHD) or stroke. In a recent randomized clinical trial called FLOWPROMOTE, researchers present a strategy to reverse atherosclerosis partially.

They tested whether aggressively lowering bad cholesterol in newly diagnosed patients using cholesterol-lowering statins can shrink and reverse plaque buildup in heart arteries. Over an 18-month treatment period, participants either took atorvastatin 40 mg daily, a standard high-dose statin, or rosuvastatin 40 mg plus ezetimibe 10 mg daily, a stronger statin combined with a medicine that blocks cholesterol absorption in the gut.

Plaque buildup in the heart’s arteries isn’t necessarily a point of no return because bringing cholesterol levels down aggressively can actually make existing plaques shrink. With combination therapy, 90% of patients saw their plaque volume decrease, compared with 75% on standard treatment. The findings are published in JAMA Cardiology.

Beyond the Trial—What Do Extension Studies Add to Randomized Clinical Trials? Clinical Trials in Context

One critical shortcoming of many clinical therapeutic trials is their focus on short-term effects, leaving unanswered questions about how participants fare in the longer term. Trial extension studies are conducted to address this gap, allowing assessment of both durability of treatment benefit (eg, whether disease remission or improvements in function are maintained or diminished over time) and long-term safety (such as incidence of delayed adverse events).1 In therapeutic trials, extension studies can mitigate the ethical burden associated with discontinuation of potentially effective treatments or long-term administration of placebo or inferior interventions among those initially assigned to the control group.2 The prospect of an extension study may also give participants greater incentive to enroll in trials, despite concerns about being assigned to the control group in the initial phase of the research. Because extension studies build on existing trial infrastructure, they also allow additional and potentially valuable information to be derived from trials that already require significant up-front investment.

Despite these advantages, several key methodological challenges arise in the design and analysis of trial extension studies. The evidence from these studies is generally framed in the context of the original clinical trial, lending greater credibility to the quality of the outcomes data as well as any causal inferences about longer-term effects. However, epidemiologically, long-term extension studies are essentially cohort studies and, in many cases, uncontrolled cohort studies given the lack of any comparison group. Thus, when longer-term trial extension studies attempt to draw conclusions about the effects of study interventions, either favorable or unfavorable, the reader is often left wondering “Compared with what?”

Some extension studies follow up participants from only the original experimental treatment group. For example, in a study examining the long-term outcomes of intermittent paliperidone palmitate in adults with schizophrenia, investigators provided rare long-term data about outcomes after a trial in a population that is challenging to study3; however, participants who relapsed, died, or withdrew from the initial trial due to adverse events were excluded from the extension. As the investigators acknowledged in JAMA Network Open,3 this effectively created an enhanced cohort study with survivor bias and without a comparison group, limiting the statistical inferences that could be made. Investigators could not determine whether participants would have had similar outcomes even if they had not continued to be exposed to the intervention.

Abstract: 1 Chinese Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China

1 Chinese Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China.

2School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Address for correspondence. Chuan-Yuan Li, PhD, Chinese Institutes for Medical Research, Beijing, China 100069. Email: [email protected].

Researchers create light-activated cages for ‘protein killer’ molecules

Researchers have created a molecular “cage” that keeps protein-degrading drug molecules inactive until they are exposed to low-energy red light. The technology, called RuPHOTACs, controls when and where these molecules become active, which could help scientists develop treatments that destroy specific proteins while limiting unwanted effects elsewhere.

The paper is published in the journal Nature Communications.

Ancient Human DNA Reveals Hidden Connections Across Ice Age Europe

At the same time, the researchers found evidence for long-term population continuity in southwestern Europe. Genomic data from Chufín Cave in northern Spain indicate that western European ancestry persisted in the region over thousands of years. The team also analysed ancient human DNA preserved directly in cave sediment. At El Mirón Cave in Cantabria, they recovered enough human nuclear DNA from a 22,000-year-old layer to determine its genetic ancestry – despite the absence of human bones or teeth. “Sedimentary DNA allows us to recover genetic information from periods where human remains are missing,” says senior author Ron Pinhasi, Department of Evolutionary Anthropology at the University of Vienna, whose team led this study. “This gives us a way to connect archaeological layers with the genetic ancestry of the people who occupied a site.” The El Mirón DNA shows that this ancestry persisted through the Last Glacial Maximum, supporting the idea of the Iberian Peninsula as an Ice Age refuge.

What mother and son reveal about mating

In southern Italy, the team analysed Ostuni1b, a male fetus and most likely the son of the previously studied woman Ostuni1. His father probably came from the same genetic population, yet the parents were not closely related – suggesting mating practices that helped avoid high levels of inbreeding. Together, the findings show that regional population continuity could coexist with genetic exchange over large distances. Gelabert’s team is now combining sedimentary DNA with advanced proteomic analyses to investigate the first trans-European expansions of modern humans and their interactions with carnivores where organic remains are scarce.

Cerebellar and frontal lobe alterations in pulmonary hypertension implicate an inflammatory lung vascular/brain axis

Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine;

2Department of Computational and Systems Biology; and.

3McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.